Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2024 | Treatment options for patients with UC who progress on chemotherapy and ICIs

Anand Sharma, MD, DPhil, MBBS, MRCP, Mount Vernon Cancer Centre, Northwood, UK, discusses treatment strategies for patients with urothelial carcinoma (UC) who progress on first-line checkpoint inhibitors (ICIs) and chemotherapy such as gemcitabine and cisplatin. Antibody-drug conjugates including sacituzumab govitecan and enfortumab vedotin, as well as FGFR inhibitors such as erdafitinib have shown promising results in clinical trials. Dr Sharma additionally highlights targeting HER2. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.